Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 221

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 221
---
ENDS A VOTE “FOR” PROPOSAL FOUR. Table of Contents 2025 PROXY STATEMENT 58

Audit Fees The Audit Committee regularly reviews and determines whether specific projects or expenditures with our independent auditors may potentially affect their independence. The Audit Committee’s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. Pre-approval is generally provided by the Audit Committee for up to one year, detailed to the particular service or category of services to be rendered and is generally subject to a specific budget. The Audit Committee may also pre-approve additional services of specific engagements on a case-by-case basis. All engagements of our independent registered public accounting firm in 2024 and 2023 were pre-approved by the audit committee. The following table sets forth the aggregate audit fees and other services provided during the indicated fiscal years. These include amounts billed and expected to be billed by our current independent auditors, KPMG, for fiscal year 2024, and by our former independent auditors, RS&J, for fiscal year 2023: Year Ended September 30, 2024 2023 Audit fees (1) $860,000 $414,250 Audit-related fees (2) 150,000 226,100 Tax Fees — — All other fees — — Total $1,010,000 $640,350 (1) Fees invoiced by KPMG and RS&J include year-end audit and periodic reviews of Forms 10-Q and 10-K. (2) Fees invoiced by KPMG and RS&J related to Comfort Letters and Consents for financings and registration statements, and other agreed-upon procedures. Table of Contents 2025 PROXY STATEMENT Audit Fees 59

Report of the Audit Committee The following is the report of the Audit Committee with respect to the Company’s audited financial statements for fiscal 2024, which include the consolidated balance sheets of the Company as of September 30, 2024 and September 30, 2023, and the related consolidated statements of operations, stockholders’ equity and cash flows for the fiscal years ended September 30, 2024, September 30, 2023 and September 30, 2022, and the notes thereto. Composition. At September 30, 2024, the Audit Committee of the Board was comprised of three directors and operated under a written charter adopted by the Board. The members of the Audit Committee for fiscal